We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Concentra Group Holdings Parent, Inc. (CON) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Concentra Group (CON - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Concentra Group is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Concentra Group is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CON's full-year earnings has moved 3.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that CON has returned about 60.6% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 0.5% on a year-to-date basis. This means that Concentra Group is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Cytokinetics (CYTK - Free Report) . The stock has returned 26.2% year-to-date.
Over the past three months, Cytokinetics' consensus EPS estimate for the current year has increased 1.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Concentra Group belongs to the Medical Services industry, which includes 72 individual stocks and currently sits at #95 in the Zacks Industry Rank. On average, this group has lost an average of 0.7% so far this year, meaning that CON is performing better in terms of year-to-date returns.
In contrast, Cytokinetics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 438 stocks and is ranked #98. Since the beginning of the year, the industry has moved +2.2%.
Investors with an interest in Medical stocks should continue to track Concentra Group and Cytokinetics. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Concentra Group Holdings Parent, Inc. (CON) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Concentra Group (CON - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Concentra Group is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Concentra Group is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CON's full-year earnings has moved 3.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that CON has returned about 60.6% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 0.5% on a year-to-date basis. This means that Concentra Group is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Cytokinetics (CYTK - Free Report) . The stock has returned 26.2% year-to-date.
Over the past three months, Cytokinetics' consensus EPS estimate for the current year has increased 1.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Concentra Group belongs to the Medical Services industry, which includes 72 individual stocks and currently sits at #95 in the Zacks Industry Rank. On average, this group has lost an average of 0.7% so far this year, meaning that CON is performing better in terms of year-to-date returns.
In contrast, Cytokinetics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 438 stocks and is ranked #98. Since the beginning of the year, the industry has moved +2.2%.
Investors with an interest in Medical stocks should continue to track Concentra Group and Cytokinetics. These stocks will be looking to continue their solid performance.